International Urology and Nephrology

, Volume 42, Issue 4, pp 959–964 | Cite as

The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph node–positive bladder cancer

  • Berkan ReşorluEmail author
  • Kadir Türkölmez
  • Gül Ergün
  • Sümer Baltacı
  • Çağatay Göğüş
  • Yaşar Bedük
Urology – Original Paper



To report the long-term follow up of patients with locally advanced bladder cancer treated with either adjuvant chemotherapy with gemcitabine/cisplatin (GC) or methotrexate, vinblastine, epirubicin, and cisplatin (MVEC) or no additional treatment after radical cystectomy, to examine various survival endpoints and factors associated with long-term survival.

Patients and methods

Seventy-eight patients undergoing radical cystectomy for pathologic stage T3, T4 or lymph node–positive (N+) bladder cancer were divided to observation group (46 patients) and adjuvant chemotherapy group (32 patients). Data were obtained for recurrence free (RFS) and overall survival (OS).


One-, 2- and 5-year RFS rates were 74, 56.8 and 51.1% for chemotherapy arm, whereas these ratios were 50.6, 31 and 27.6% for control arm, respectively (P = 0.032). RFS rates were significantly better in patients with lymph node–negative disease than in those with positive lymph nodes for control arm (P = 0.007), but for the chemotherapy arm there was no statistical difference between patients with lymph node–negative and –positive disease (P = 0.28). Mean OS and RFS times were 31.03 and 28.4 months for chemotherapy arm, while they were 22.17 and 18.09 months for control arm, respectively (P = 0.142, P = 0.196). On multivariate analysis, lymph node metastasis and adjuvant chemotherapy remained significant independent prognostic factors for cancer-specific survival.


Bladder cancer is chemosensitive, and using adjuvant chemotherapy is likely to improve the outcome of local treatment and to decrease the rates of distant metastases.


Adjuvant chemotherapy Bladder cancer Cisplatin Prognosis Radical cystectomy 


  1. 1.
    Jemal A, Murray T, Ward E et al (2005) Cancer statistics. CA Cancer J Clin 55:10–30CrossRefPubMedGoogle Scholar
  2. 2.
    Herr HW, Dotan Z, Donat SM et al (2007) Defining optimal therapy for muscle invasive bladder cancer. J Urol 177:437–443CrossRefPubMedGoogle Scholar
  3. 3.
    Lehmann L, Retz M, Wiemers C et al (2005) Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: Results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23:4963–4974CrossRefPubMedGoogle Scholar
  4. 4.
    Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMedGoogle Scholar
  5. 5.
    Boccardo F, Palmeri L (2006) Adjuvant chemotherapy of bladder cancer. Ann Oncol 17:129–132CrossRefGoogle Scholar
  6. 6.
    Logothesis CJ, Johnson DE, Chong C et al (1988) Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6:1590–1596Google Scholar
  7. 7.
    Michael M, Tannock IF, Czaykowski PM et al (1998) Adjuvant chemotherapy for high risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. Br J Urol 82:366–372PubMedGoogle Scholar
  8. 8.
    Skinner DG, Daniels JR, Russell CA et al (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459–464PubMedGoogle Scholar
  9. 9.
    Walz J, Shariat SF, Suardi N et al (2008) Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int 101:1356–1361CrossRefPubMedGoogle Scholar
  10. 10.
    Stockle M, Meyenburg W, Wellek S et al (1992) Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148:302–306PubMedGoogle Scholar
  11. 11.
    Stockle M, Wellek S, Meyenburg W et al (1996) Radical cystectomy with or without adjuvant polychemotherapy for nonorgan-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48:868–875CrossRefPubMedGoogle Scholar
  12. 12.
    Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495–499CrossRefPubMedGoogle Scholar
  13. 13.
    Sylvester R, Sternberg C (2000) The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 11:851–856CrossRefPubMedGoogle Scholar
  14. 14.
    Bono AV, Benvenuti C, Reali L et al (1989) Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 303:533–540PubMedGoogle Scholar
  15. 15.
    Collaboration ABCAM-a (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:189–199CrossRefGoogle Scholar
  16. 16.
    Boccardo F, Palmeri L (2006) Adjuvant chemotherapy of bladder cancer. Ann Oncol 17(suppl 5):129–132CrossRefGoogle Scholar
  17. 17.
    Rosenberg JE, Carrol PR, Small EJ (2005) Update on chemotherapy for advanced bladder cancer. J Urol 174:14–20CrossRefPubMedGoogle Scholar
  18. 18.
    Boyar M, Petrylak DP (2005) Adjuvant chemotherapy for transitional cell carcinoma of the bladder: paradigms for the design of clinical trials. Curr Oncol Rep 7:207–214CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, B.V. 2010

Authors and Affiliations

  • Berkan Reşorlu
    • 1
    • 4
    Email author
  • Kadir Türkölmez
    • 2
  • Gül Ergün
    • 3
  • Sümer Baltacı
    • 2
  • Çağatay Göğüş
    • 2
  • Yaşar Bedük
    • 2
  1. 1.Department of UrologyKecioren Training and Research HospitalAnkaraTurkey
  2. 2.Faculty of Medicine, Department of UrologyUniversity of AnkaraAnkaraTurkey
  3. 3.Faculty of Science, Department of StatisticsUniversity of HacettepeAnkaraTurkey
  4. 4.Kecioren, AnkaraTurkey

Personalised recommendations